Neoral Related Published Studies
Well-designed clinical trials related to Neoral (Cyclosporine)
Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with
topical cyclosporine 0.05%. [2014]
Efficacy of cyclosporine for chronic, refractory stomatitis in cats: A
randomized, placebo-controlled, double-blinded clinical study. [2013]
The effect of prethrombolytic cyclosporine-A injection on clinical outcome of
acute anterior ST-elevation myocardial infarction. [2013]
Effect of cyclosporine-A on orthodontic tooth movement in rats. [2011.11]
Safety and toxicology of cyclosporine in propylene glycol after 9-month aerosol exposure to beagle dogs. [2011.08]
Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. [2011.07]
Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). [2011.05.15]
A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. [2011.04.28]
Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. [2011.04]
Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study. [2011.03]
Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study. [2011.02]
Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. [2011.01.20]
Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis--a clinical randomized controlled trial. [2011.01]
An investigation comparing the efficacy of topical ocular application of tacrolimus and cyclosporine in dogs. [2011]
A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. [2010.12.15]
Cyclosporine and mycophenolate mofetil 48 hours before renal transplantation enables the use of low cyclosporine doses and achieves better graft function. [2010.12]
Assessment of bioequivalence of a generic cyclosporine (Equoral) by a prospective randomized controlled trial on allogeneic stem cell transplant recipients. [2010.11]
Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. [2010.11]
Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study. [2010.10]
Preliminary results of a prospective randomized study of cyclosporine versus tacrolimus in the development of cardiac allograft vasculopathy at 1 year after heart transplantation. [2010.10]
A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome. [2010.10]
Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. [2010.10]
Influence of purple grape juice in cyclosporine bioavailability. [2010.09]
A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. [2010.09]
A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial. [2010.08]
Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial. [2010.08]
Cyclosporine 0.05% to improve visual outcomes after multifocal intraocular lens implantation. [2010.07]
Sotrastaurin and cyclosporine drug interaction study in healthy subjects. [2010.07]
Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis--a clinical randomized controlled trial. [2010.06.24]
Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus. [2010.06]
Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. [2010.06]
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. [2010.05.01]
Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. [2010.05]
Can cyclosporine blood level be reduced to half after heart transplantation? [2010.04]
Topical cyclosporine 0.05% for the prevention of dry eye disease progression. [2010.04]
Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: results of a pilot study. [2010.04]
Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction. [2010.03.01]
Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, open-label trial. [2010.03]
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). [2010.03]
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). [2010.03]
Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. [2010.02]
Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up. [2010.02]
Inhaled cyclosporine and pulmonary function in lung transplant recipients. [2010.02]
The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study. [2010.01]
Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. [2010.01]
Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome. [2010.01]
Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a
randomized, double-blind, multicenter study. [2010]
Efficacy of topical cyclosporine A 2% in prevention of graft rejection in
high-risk keratoplasty: a randomized controlled trial. [2010]
Effect of cyclosporine on blood pressure. [2010]
Effects of postoperative cyclosporine ophthalmic emulsion 0.05% (Restasis) following glaucoma surgery. [2009.12]
Long-term graft function with tacrolimus and cyclosporine in renal transplantation: paired kidney analysis. [2009.12]
Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. [2009.11.27]
Interstitial fibrosis quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus. [2009.11]
Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. [2009.09.22]
A bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients. [2009.09]
Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine A to everolimus. [2009.07.27]
Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. [2009.07.15]
Inhaled Cyclosporine and Pulmonary Function in Lung Transplant Recipients. [2009.07.06]
Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine. [2009.07]
Experience with cyclosporine in children with chronic idiopathic urticaria. [2009.07]
Cyclosporine withdrawal improves long-term graft survival in renal transplantation. [2009.06.27]
Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study. [2009.06]
Efficacy of topical cyclosporine for the treatment of ocular rosacea. [2009.06]
Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. [2009.05]
Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. [2009.05]
Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects. [2009.04]
Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. [2009.04]
Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil. [2009.03.27]
Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. [2009.03]
Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. [2009.02]
A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. [2009.02]
CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. [2008.12]
Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids. [2008.11.15]
Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. [2008.11.15]
Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. [2008.11]
Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. [2008.11]
Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. [2008.11]
Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. [2008.10.15]
Dosing and safety of cyclosporine in patients with severe brain injury. [2008.10]
Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus. [2008.10]
Effect of cyclosporine on reperfusion injury in acute myocardial infarction. [2008.07.31]
Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. [2008.07.12]
CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. [2008.06]
Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. [2008.05.15]
Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. [2008.05]
Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction. [2008.04.15]
Cyclosporine 0.05% ophthalmic preparation to aid recovery from loss of corneal sensitivity after LASIK. [2008.04]
Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. [2008.04]
Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium. [2008.04]
Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. [2008.02.15]
A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients. [2008.02]
A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. [2008.02]
Effect of multiple oral dosing of fluconazole on the pharmacokinetics of cyclosporine in healthy beagles. [2008.01]
Cyclosporine pharmacokinetics and blood pressure responses after conversion to once-daily dosing in maintenance liver transplant patients. [2008.01]
Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes. [2008.01]
ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia--systematic review and meta-analysis. [2008]
Topical cyclosporine A in the prevention of pterygium recurrence. [2008]
A comparison of combination therapy (cyclosporine plus prednisolone) with sole prednisolone therapy in 7 dogs with necrotizing meningoencephalitis. [2007.12]
Antithymocyte globulin and cyclosporine for treatment of 44 children with hepatitis associated aplastic anemia. [2007.12]
Conversion of cyclosporine to tacrolimus in stable renal allograft recipients: quantification of effects on the severity of gingival enlargement and hirsutism and patient-reported outcomes. [2007.12]
Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. [2007.11]
|